Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C.
about
The phantom menace.Comparison of Conventional PCR with Real-Time PCR and Branched DNA-Based Assays for Hepatitis C Virus RNA Quantification and Clinical Significance for Genotypes 1 to 5Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine proteaseRibavirin Antagonizes the In Vitro Anti-Hepatitis C Virus Activity of 2'-C-Methylcytidine, the Active Component of ValopicitabineViral Determinants of Resistance to Treatment in Patients with Hepatitis CUse of Sequence Analysis of the NS5B Region for Routine Genotyping of Hepatitis C Virus with Reference to C/E1 and 5' Untranslated Region SequencesDiscovery and Characterization of Substituted Diphenyl Heterocyclic Compounds as Potent and Selective Inhibitors of Hepatitis C Virus ReplicationPreclinical Characteristics of the Hepatitis C Virus NS3/4A Protease Inhibitor ITMN-191 (R7227)MK-7009, a Potent and Selective Inhibitor of Hepatitis C Virus NS3/4A ProteaseHCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitorsA new stochastic model for subgenomic hepatitis C virus replication considers drug resistant mutantsThe unfinished legacy of liver transplantation: emphasis on immunology.Influence of a priori Information, Designs, and Undetectable Data on Individual Parameters Estimation and Prediction of Hepatitis C Treatment Outcome.Mechanistic studies of electrophilic protease inhibitors of full length hepatic C virus (HCV) NS3.Development of an intergenotypic hepatitis C virus (HCV) cell culture method to assess antiviral susceptibilities and resistance development of HCV NS3 protease genes from HCV genotypes 1 to 6Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modelingTreatment of hepatitis C virus infectionImmunosuppression for liver transplantation in HCV-infected patients: mechanism-based principles.Direct-acting antivirals for chronic hepatitis C.Inhibition of protease-inhibitor-resistant hepatitis C virus replicons and infectious virus by intracellular intrabodies.New developments in small molecular compounds for anti-hepatitis C virus (HCV) therapy.Sequence diversity of hepatitis C virus: implications for immune control and therapy.Challenges and successes in developing new therapies for hepatitis C.Established and emerging therapies for the treatment of viral hepatitis.Treating viral hepatitis C: efficacy, side effects, and complications.Improving anti-hepatitis C virus therapy.Antiviral treatment of hepatitis C.Targets of emerging therapies for viral hepatitis B and C.New treatment strategies against hepatitis C viral infection.Present and future therapy for hepatitis C virus.Improving the treatment of hepatitis C infection in the UK.Toll-like receptors, RIG-I-like RNA helicases and the antiviral innate immune response.Novel protease and polymerase inhibitors for the treatment of hepatitis C virus infection.Old and emerging therapies in chronic hepatitis C: an update.HCV genetic variability: from quasispecies evolution to genotype classification.Serine protease inhibitors as anti-hepatitis C virus agents.Antiviral therapy for hepatitis C virus: beyond the standard of care.Boceprevir: a novel NS3/4 protease inhibitor for the treatment of hepatitis C.Novel therapies for hepatitis C - one pill fits all?Hepatitis C virus infection and related liver disease: the quest for the best animal model
P2860
Q27472943-B0F42C4E-2030-4847-976D-387810CDC65BQ27473038-FBA35209-A999-4EBF-817F-8833E4047C67Q27473126-8F970EC3-FB25-4D80-A43A-0395D42DB445Q27477522-8B4E507A-5B60-41CC-ACF9-74BEFC4FBC23Q27478062-47289863-160B-411F-AFFE-0B812BD78B82Q27478359-355B0DFD-4DED-4257-8248-597571BBCC46Q27485724-49050C65-EB84-4396-A360-C22CF8FB49B6Q27487391-CACB58EB-F4C8-40B6-8309-6CC0852AC857Q27490545-3FDE0958-5A95-4EA9-BF9B-21D8265C27CCQ28481038-4C9CE392-00D7-422B-9C93-40703A6E723CQ28541048-7A7C9206-5DF2-4472-9FB3-FC9F999A72D7Q30352760-CCCBDF50-9BDD-4A8F-BDFD-D41A4E4615CBQ30655795-D0F323B0-3AD8-431C-8E4C-7BB54E13E52AQ33285370-76BA2A0A-7628-4B64-AC00-BA1042E1C730Q33826766-2F0FCC84-BCBB-495C-B3D2-781EBA41E254Q33899320-F8762ADE-E345-4769-86B1-2DC0526FF3B6Q34099424-20F961C3-077D-494D-B23E-065F06E2CD2CQ34232434-5F5E6433-A25D-4A3A-8E34-9E7C70A73F26Q34557595-017AB9F1-C665-4705-80A8-AC1375F3A7CDQ35565927-E0DEA2AB-4052-40B5-BB72-1C777950C23CQ35653358-F223E300-11C1-4CFC-9968-A2E00C012626Q36179696-B5A989D1-A281-4D52-B6F3-326C869068AAQ36233823-BC7F99D1-2732-484E-A395-7F6A1B98EC13Q36478120-01419C38-5F3D-4280-896C-125DE54134D0Q36564615-CCDB190C-5A58-4C78-8AE1-448632F49933Q36569749-AAFB005D-828D-47BF-8156-523F59363B17Q36613917-1EC23E4C-381D-4216-A5A8-75B6A311B75CQ36653655-C14268E0-943E-4FA3-98B2-5AA7DADB44DBQ36655935-A964C426-9676-411C-B060-8700FC198535Q36670887-5B4DE2FE-247B-4590-8376-1C673AABEB72Q36719683-EDDBB020-B559-413B-A487-B7A2AD74DD6BQ36898663-9A3B445D-0DCB-4656-8E2B-D4C7BD9467F3Q36904844-BBE9D447-2CBF-4BEC-A15C-5AC6BF6E06B2Q37035294-6E0C14A3-A90B-4CF3-84C3-300A48429836Q37425275-5D3E145E-D960-4D6C-AA46-63BCC407AC61Q37503337-0CAB3581-8CE8-404A-A5E1-7A35B5C727DAQ37945201-AB1F0DC8-DB89-4711-878D-FF2D54D5D1C1Q37990840-841BD7FF-9655-4BD0-A694-405EB68E406CQ38117549-207E231A-E086-4CC0-9CAF-353ABB580D05Q38125192-F3C3E0DD-5B6C-4D24-A870-09C4FD571873
P2860
Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Antiviral efficacy of NS3-seri ...... genotype 2 and 3 hepatitis C.
@en
Antiviral efficacy of NS3-seri ...... genotype 2 and 3 hepatitis C.
@nl
type
label
Antiviral efficacy of NS3-seri ...... genotype 2 and 3 hepatitis C.
@en
Antiviral efficacy of NS3-seri ...... genotype 2 and 3 hepatitis C.
@nl
prefLabel
Antiviral efficacy of NS3-seri ...... genotype 2 and 3 hepatitis C.
@en
Antiviral efficacy of NS3-seri ...... genotype 2 and 3 hepatitis C.
@nl
P2093
P356
P1433
P1476
Antiviral efficacy of NS3-seri ...... genotype 2 and 3 hepatitis C.
@en
P2093
Chan-Loi Yong
Cristina Avendano
Gerhard G Steinmann
Gerhard Nehmiz
Heiner Wedemeyer
Henk W Reesink
Holger Hinrichsen
Markus Reiser
Yves Benhamou
P304
P356
10.1002/HEP.20612
P407
P577
2005-04-01T00:00:00Z